An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).

Authors: Jacob Sands, Jason Timothy Henry, Alexander I. Spira, Daruka Mahadevan, Catherine Belle Meador, Jared Weiss, Abdul Rafeh Naqash, Jennifer A. Chan, Himisha Beltran, Grace H McGregor, Rita Laeufle, Hui Zou

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8128

Source: Full article

---

Abstract

TPS8128